Healthcare–associated Pneumonia Market Size 2023 | Forecast till 2033

 

The newly published report by IMARC Group, titled, ”Healthcare–associated Pneumonia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033″, presents a comprehensive analysis of the healthcare-associated pneumonia market. The report provides an overview of the market trends, growth prospects, investment opportunities, and industry prospects, as well as an analysis of the disease overview, market scenario, and growth trends. In addition, the report offers competitor analysis, regional analysis, and recent advancements in the global market. The report also highlights key segments and market drivers, as well as challenges faced by industry players.

Healthcare-associated pneumonia (HCAP) represents a type of pneumonia that occurs owing to prior contact with a healthcare environment. It is associated with several risk factors, including home infusion therapy, dialysis, hospitalization in the past, residing in a nursing center, immunocompromised state, etc. HCAP is characterized by unease, reduced appetite, cough with greenish or mucus-like phlegm, unpleasantness, abdominal discomfort, and difficulty breathing. Other symptoms include sharp chest pain that worsens with inhalation and exhalation or coughing, diminished blood pressure, and an increased heart rate. Diagnosing this condition begins with a chest x-ray or CT scan to examine the lungs and arterial blood gases to calculate the respiratory rate. It is accompanied by a sputum culture to detect the microorganisms provoking pneumonia and a pulse oximetry test to observe blood oxygen levels. The diagnosis also involves bronchoscopy, which is crucial to avoid the possibility of an incorrect prognosis.

Request a Free Sample Report: https://www.imarcgroup.com/healthcare-associated-pneumonia-market/requestsample

Market Trend:

The escalating prevalence of chronic ailments, such as cardiac arrest, brain stroke, kidney failure, etc., requiring surgical intervention and prolonged hospital stays, is primarily driving the healthcare-associated pneumonia market. Besides this, the rising number of patients admitted to medical facilities who have antibacterial resistance, on account of the excessive usage of antibiotics, is further augmenting the market growth. Moreover, the growing popularity of various PCR-based platforms for diagnosing HCAP, which offers high detection efficiency, thereby reducing cost and time, is also catalyzing the global market. Apart from this, the extensive utilization of combination therapy to treat this condition, since it reduces the chances of resistance developed by the bacteria and provides a broad spectrum of coverage, is acting as another significant growth-inducing factor. Furthermore, the elevating requirement for point-of-care testing products, owing to their convenience, quicker diagnosis, and improved patient outcomes, is expected to bolster the healthcare-associated pneumonia market in the coming years.

Report Period:

• Base Year: 2022
• Historical Period: 2017-2022
• Market Forecast: 2023-2033

Countries Included:

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the healthcare-associated pneumonia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the healthcare-associated pneumonia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Regulatory Status

Ask an Analyst for Report Customization with TOC & List of figures: https://www.imarcgroup.com/healthcare-associated-pneumonia-market

Key Questions Answered in this Report:

• How has the healthcare-associated pneumonia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2022 and how are they expected to perform till 2033?
• What was the country-wise size of the healthcare-associated pneumonia market across the seven major markets in 2022 and what will it look like in 2033?
• What is the growth rate of the healthcare-associated pneumonia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Browse the Latest Research Report:

Catheter-Related Bloodstream Infections (CRBSIs) Market Report 2023-2033

Androgenetic Alopecia Market Report 2023-2033

Urinary Retention Market Report 2023-2033

Down Syndrome Market Report 2023-2033

About Us: –

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800